# A Study of JNJ-75229414 for Metastatic Castration-resistant Prostate Cancer Participants

> **NCT05022849** · PHASE1 · COMPLETED · sponsor: **Janssen Research & Development, LLC** · enrollment: 15 (actual)

## Conditions studied

- Prostatic Neoplasms

## Interventions

- **DRUG:** JNJ-75229414
- **DRUG:** Bridging Therapy

## Key facts

- **NCT ID:** NCT05022849
- **Lead sponsor:** Janssen Research & Development, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-09-28
- **Primary completion:** 2026-03-11
- **Final completion:** 2026-03-11
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2026-04-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05022849

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05022849, "A Study of JNJ-75229414 for Metastatic Castration-resistant Prostate Cancer Participants". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05022849. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*